The <scp>PINNACLE</scp> study: A multicentre phase <scp>II</scp> trial of nilotinib in combination with pegylated interferon‐α2b in newly diagnosed chronic phase chronic myeloid leukaemia
David T. Yeung(Royal Adelaide Hospital), the Australasian Leukaemia and Lymphoma Group, Susan Branford(South Australia Pathology), Rosemary Harrup(University of Tasmania), Deepmala Mazumdar(Australasian Leukaemia and Lymphoma Group), Christopher Arthur(Royal North Shore Hospital), Deborah L. White(ANZCHOG), Naranie Shanmuganathan(South Australia Pathology), Anthony K. Mills(Princess Alexandra Hospital), David Kipp(Geelong Hospital), Ilona Cunningham(The University of Sydney), Anthony P. Schwarer(The Alfred Hospital), Philip Rowlings(Calvary Mater Newcastle Hospital), Sher Gul Gazdar(Australasian Leukaemia and Lymphoma Group), John Reynolds(Monash University), Jake Shortt(Monash Medical Centre), Timothy Hughes(Royal Adelaide Hospital), Andrew P. Grigg(Austin Health), Agnes S. M. Yong(Royal Perth Hospital), David M. Ross(Flinders Medical Centre), Robert Weinkove(Malaghan Institute of Medical Research), Kathryn Jackson(Sunshine Coast University Hospital), Nicholas Viiala(Liverpool Hospital)
Cited by 1
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453